Antimycotic gel having high active compound release

Details Antimycotic gel having high active compound release Antimycotic gel having high active compound release

2006-04-11

2006-04-11

Webman, Edward J. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S944000

Reexamination Certificate

active

07026337

ABSTRACT:
A pharmaceutical preparation comprising a hydrophilic gel-forming agent, water and a compound of the formula Iis suitable for the treatment and prophylaxis of dermatomycoses.

REFERENCES:
patent: 3968118 (1976-07-01), Lohaus et al.
patent: 4185106 (1980-01-01), Dittmar et al.
patent: 4699924 (1987-10-01), Durrant et al.
patent: 4797409 (1989-01-01), Lohaus et al.
patent: 4957730 (1990-09-01), Bohn et al.
patent: 5066484 (1991-11-01), Castrogiovanni et al.
patent: 5071639 (1991-12-01), Soyama et al.
patent: 5120530 (1992-06-01), Ferro et al.
patent: 5132107 (1992-07-01), Lange
patent: 5264206 (1993-11-01), Bohn et al.
patent: 5346692 (1994-09-01), Wohlrab et al.
patent: 5356907 (1994-10-01), Clemence et al.
patent: 5395843 (1995-03-01), Clemence et al.
patent: 5494658 (1996-02-01), Hänel et al.
patent: 5510100 (1996-04-01), Picard et al.
patent: 5559130 (1996-09-01), Clemence et al.
patent: 5603939 (1997-02-01), Ser
patent: 5609854 (1997-03-01), Guerrero et al.
patent: 5612327 (1997-03-01), Makino et al.
patent: 5650145 (1997-07-01), Saint-Leger
patent: 5675013 (1997-10-01), Hani et al.
patent: 5683681 (1997-11-01), Ramin et al.
patent: 5753600 (1998-05-01), Kamegai et al.
patent: 5756108 (1998-05-01), Ribier et al.
patent: 5866105 (1999-02-01), Richter et al.
patent: 6162420 (2000-12-01), Bohn et al.
patent: 6455551 (2002-09-01), Kraemer et al.
patent: 6469033 (2002-10-01), Bohn et al.
patent: 2003/0086881 (2003-05-01), Bohn et al.
patent: 2004/0039030 (2004-02-01), Bohn et al.
patent: 716 208 (1998-04-01), None
patent: 2134293 (1995-04-01), None
patent: 2134304 (1995-04-01), None
patent: 31 40 954 (1983-05-01), None
patent: 38 26 914 (1990-02-01), None
patent: 0 218 410 (1987-04-01), None
patent: 0 241 918 (1987-10-01), None
patent: 0 313 305 (1989-04-01), None
patent: 0 381 446 (1990-08-01), None
patent: 0 515 312 (1992-11-01), None
patent: 0 646 369 (1995-04-01), None
patent: 0 649 660 (1995-04-01), None
patent: 0 680 745 (1995-11-01), None
patent: 0 680 745 (1995-11-01), None
patent: 0 771 187 (1997-05-01), None
patent: 2 618 068 (1989-01-01), None
patent: 2 685 638 (1993-07-01), None
patent: 2 685 867 (1993-07-01), None
patent: 2 694 694 (1994-02-01), None
patent: 2 207 051 (1989-01-01), None
patent: 2 208 149 (1989-03-01), None
patent: 202 098 (1990-03-01), None
patent: 208 007 (1991-05-01), None
patent: 61-69721 (1986-04-01), None
patent: WO 87/02580 (1987-05-01), None
patent: WO 94/05256 (1994-03-01), None
patent: WO 95/17165 (1995-06-01), None
patent: WO 96/02226 (1996-02-01), None
patent: WO 96/13247 (1996-05-01), None
patent: WO 96/19186 (1996-06-01), None
patent: WO 96/29045 (1996-09-01), None
patent: WO 96/29056 (1996-09-01), None
patent: WO 97/20560 (1997-06-01), None
patent: WO 98/13009 (1998-04-01), None
patent: WO 98/13042 (1998-04-01), None
patent: WO 98/13043 (1998-04-01), None
patent: WO 99/39680 (1999-08-01), None
patent: WO 99/49835 (1999-10-01), None
Abrams et al., “Ciclopirox Olamine: A Hydroxypyridone Antifungal Agent,”Clinics in Dermatology, vol. 9, pp. 471-477 (1992).
Aly et al., “Common Superficial Fungal Infectious in Patients with AIDS,”Clin. Infect. Diseases, vol. 22, Suppl. 2, pp. S128-S132 (1996).
Amos et al., “Clinical efficacy of Polytar AF (Fongitar) and Nizoral Scalp Treatments in Patients with Dandruff/Seborrhoeic Dermatitis,”Journal of Dermatological Treatment, vol. 5, pp. 127-130 (1994).
Braga et al., “Inhibition of Candida Albicans Adhesiveness to Human Buccal and Vaginal Cells by Sub-inhibitory Concentrations of Rilopirox,”Arzneim.-Forsch./Drug Res.,vol. 45, No. 1, pp. 84-87 (1995).
Corte et al., “Topische Anwendung einer 0.1%igen Ciclopiroxolamin-Lösung zur Behandlung der Pityriasis versicolor, Topical Application of a 0.1% Ciclopiroxolamine Solution for the Treatment of Pityriasis versicolor,”Mycoses, vol. 32, No. 4, pp. 200-203 (1989). (English Abstract).
Cullen et al., “Treatment of Tinea Versicolor with a New Antifungal Agent, Ciclopirox Olamine Cream 1%,”Clinical Therapeutics, vol. 7, No. 5, pp. 574-583 (1985).
Faergemann, J., “Pityriasis Versicolor,”Seminars in Dermatology, vol. 12, No. 4, pp. 276-279 (1993).
Grosshans et al., “L'Eczema Seborrheique (La Pityrosporose),”Ann. Dermatol. Venereol., vol. 115, pp. 79-86 (1988). (English Abstract).
Hanel et al., “Evaluation of Fungicidal Actionin Vitroand in a Skin Model Considering the Influence of Penetration Kinetics of Various Standard Antimycotics,”Annals New York Academy of Sciences, vol. 544, pp. 329-337 (1988).
Hanel et al., “A Comparison of Bifonazole and Ciclopiroxolamine:in Vitro, Animal, and Clinical Studies,”Mycoses, vol. 31, No. 12, pp. 632-640 (1988).
Hanel et al., “Treatment of Seborrhoic Eczema Using an Antimycotic with Antiphlogistic Properties,”Mycoses,vol. 34, Suppl. 91-93 (1991). (English Summary).
Martindale, The Extra Pharmacopoeia 30thEd., London,The Pharmaceutical Press, pp. 332, 1609 (1993).
Montana et al., “A Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Fungoid Tincture® in Patients with Distal Subungual Onychomycosis of the Toes,”Cutis, 53:313-316 (1994).
Plewig et al., “Seborrheic Dermatitis,”FitzPatrick's Dermatology in General Medicine, 5thEd., Ch. 126, pp. 1-17 CD-Rom (1999).
Przekop et al., “Ciclopirox Olamine, An Antifungal Modulator of Neutrophil Function and Infiltrate in Cutaneous Inflammation,” J. Investigative Dermatology, vol. 102, No. 4, (SID Abstracts) p. 593, (1994).
Raether et al., “Rilopriox-a New Hydroxypyridone Antifungal with Fungicidal properties,”Mycoses, vol. 33, No. 4, pp. 191-202 (1990).
Rivalland, P., et al., “Evaluation of the antifungal activity of two derivatives and in vivo innocuity tests of shampooings with regard to antidandruff formulations,” Abstract,Int. J. Cosmet. Sci.,vol. 16, No. 2, pp. 77-83 (1994).
Saint-Leger et al., “the Role of the Resident Microflora in the Pathogenesis of Dandruff,”J. Soc. Cosmet. Chem., vol. 40, No. 2, pp. 109-117 (1989).
Schofer, H., “Therapie des seborrhoischen Ekzems bei HIV-Infektion,” Forschung und Praxis, 98 Seite III, (1990).
Shapiro et al., “Medicated Shampoos,”Clinics in Dermatology, vol. 14, pp. 123-128 (1996).
Shuster, S., “Dandruff, Seborrhoeic Dermatitis, and Pityrosporum Ovale,”Cosmetics and Toiletries, vol. 103, pp. 87-91 (1988).
Yoshimasa et al., “the Sebum Lipid Assimilation and The Growth Inhibition ofPityrosporum ovale(1st report),”J. Soc. Cosmet. Chem. Japan, vol. 22, No. 3, pp. 165-170 (1988). (English Abstract).
“Scaly Dermatoses,”Handbook of Nonprescription Drugs, American Pharm. Assoc., Ch. 26, pp. 550-552 (1996).
“Seborrheic Dermatitis and Dandruff,” Manual of Dermatologic Therapeutics, 5thEd., Ch. 29, pp. 164-167 (1995).
Abstract of JP 07-082126 A (1993).
U.S. Appl. No. 09/077,194, filed May 26, 1998, Bohn et al.
Derwent Abstract No. 95-325488 for JP 07 223 971 A (Aug. 22, 1995).

Affiliated with

Also associated with

Rating

Antimycotic gel having high active compound release does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antimycotic gel having high active compound release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimycotic gel having high active compound release will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3532876